Chembio Diagnostics, Inc.

Chembio Diagnostics, Inc. specializes in developing and manufacturing rapid point-of-care (POC) diagnostic tests for infectious diseases. Founded in 1985, the company has been a key player in the POC testing field since the late 1990s. Chembio is known for its innovative solutions that deliver quick and reliable results using a small drop of fingertip blood, typically within about 15 minutes. The company's product lineup includes lateral flow rapid tests and its proprietary Dual Path Platform (DPP) technology. Key offerings feature rapid tests for detecting antibodies to HIV types 1 and 2, syphilis, and Hepatitis C. Chembio holds two of the four FDA-approved and CLIA-waived HIV 1-2 rapid test devices available. Its DPP HIV-Syphilis multiplex test can detect antibodies to both HIV and syphilis simultaneously. Chembio serves a diverse customer base, including medical laboratories, hospitals, public health organizations, and retail establishments, both in the U.S. and internationally. The company is headquartered in Hauppauge, New York, and employs over 300 people.

• Employees 190
• Founded 1986
• Annual Revenue $48339000
• Total Funding $20678000